Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Biopharmaceutical Report I Issue18_December 2018 Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study...
top of page
Search
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake
Biopharmaceutical Report II Issue17_July 2018 Eisai’s (TYO:4523) Lenvima (lenvatinib) has a clear path to approval in first-line...
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval
Biopharmaceutical Report I Issue17_July 2018 Immunomedics’ (NASDAQ:IMMU) Phase I/ II sacituzumab govitecan hormone receptor positive...
Shooting for the Universe
Biopharmaceutical Report III Issue16_April 2018 SHOOTING FOR THE UNIVERSE By Michael Leviten, Senior Writer CureVac AG is bringing a new...
Biosimilar Uptake Still Plagued by Interchangeability Hurdles
Biopharmaceutical Report II Issue17_July 2018 Biosimilar interchangeability with reference biologics remains a challenge years after...
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments
Biopharmaceutical Report I Issue16_April 2018 Alnylam’s (NASDAQ:ALNY) trade secrets litigation case against Dicerna (NASDAQ:DRNA) could...
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica
Biopharmaceutical Report II Issue15_November 2017 BeiGene’s (NASDAQ:BGNE) BGB-3111 for Waldenström’s macroglobulinemia (WM) will need...
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations
Biopharmaceutical Report I Issue15_November 2017 Corbus Pharmaceuticals’ (NASDAQ:CRBP) Phase II study of anabasum in skin-predominant...
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery
Biopharmaceutical Report III Issue14_July 2017 BY EMILY CUKIER-MEISNER, SENIOR WRITER Dong-A ST Co. Ltd. has spent the last four years...
Medical Device: Growing Cybersecurity Threat and Need for More Regulation
Biopharmaceutical Report II Issue14_July 2017 Despite an expected increase in the frequency in cybersecurity threats in the near future...
bottom of page